OREANDA-NEWS. On August 02, 2013 the Commission of the Office of the Federal Antimonopoly Service in the Nizhny Novgorod region has issued its decision, where it granted the application of OOO “AnviLab” against OOO “VISMi”.

Activity of OOO “VISMi” containing signs of unfair competition was the reason for application to the Antimonopoly Service. Thus, VISMi was merchandising the drug “AnGricaps maxima” within the territory of the Nizhny Novgorod region formula of which was protected by the patent taken up by OOO “AnviLab”.

This violation of rights to intellectual property, unfair competition and negligence of Russian legislation forced AnviLab to look to the Federal Antimonopoly Service for protection. In fact, as was known, AnviLab delivered “AnviMax” and “Antigrippin maximum” drugs to the Nizhny Novgorod region, and the activity of VISMi damages sales of these popular anti-cold medicines.

In May 2013 the Office of the Federal Antimonopoly Service started proceeding in the case. As it turned out during the investigation the drug “AnGricaps maxima” had only a Belorussian patent that didn't give it the distribution right within the territory of the Russian Federation where the EA patent No. 008675 “Antiinfluenzal Medication” owned by OOO “AnviLab” was in effect. The Office of the Federal Antimonopoly Service detected in the activity of VISMi signs of unfair competition violating the rights of OOO “AnviLab”. And on July 30, 2013 the Office of the Federal Antimonopoly Service decided to recognize the activity of VISMi as violating the law “On Protection of Competition” in article 14, part 1, clause 4, as well as to issue the order on cessation of violation of antimonopoly legislation to OOO “VISMi”.

Protek group, comprising AnviLab, is intended to further protect its interests and fight against unfair competition violating rights and causing financial and moral damage to any enterprises which belong to this group. In Protek group they are sure that honest and transparent business of Russian and foreign pharmaceutical companies will positively reflect on all players of pharmaceutical market of Russia.